Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Ayisha Sharma / endpoints - Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target, but drugmakers are now entering the next-generation era as ...
AI Summary: Novartis agreed to pay $2 billion upfront to acquire Synnovation’s mutant‑selective PI3Kα inhibitor, a bet to revive and strengthen PI3K‑targeting combination strategies in breast cancer. The deal swaps in external innovation for internal development speed, shoring up the company’s oncology pipeline while quietly admitting buying is sometimes faster than building.
Innovative research captures emotional and social realities of denture wearers
medicalxpress - Researchers at the University of Sheffield have developed a new patient-focused tool designed to better understand the lived experience of people wearing removable partial dentures. In their study published in the journal Gerodontology, the researchers in…
AI Summary: An international ACT for Children delegation visited Yerevan to support Armenia’s pediatric oncology services through training, resource sharing, and collaborative program development. The visit focused on strengthening local clinical capacity, improving access to treatments, and forging partnerships to advance childhood cancer care—practical help rather than platitudes, with an eye on sustainable improvements.
- Global systems and communication: policy, partnerships, and cultural context (3)
- OTHER: Unrelated health research (denture study) (1)
- Survivorship care: long-term needs, nursing, and AI solutions (3)
- Yerevan visit: ACT for Children strengthens local pediatric oncology care (3)
- All Other Stories